Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection

Andrew Hill,Ahmed Abdulamir,Sabeena Ahmed,Asma Asghar,Olufemi Emmanuel Babalola,Rabia Basri,Carlos Chaccour,Aijaz Zeeshan Khan Chachar,Abu Tauib Mohammed Chowdhury,Ahmed Elgazzar,Leah Ellis,Jonathan Falconer,Anna Garratt,Basma Hany,Hashim A Hashim,Wasim Ul Haque,Arshad Hayat,Shuixiang He,Ramin Jamshidian,Wasif Ali Khan,Ravi Kirti,Alejandro Krolewiecki,Carlos Lanusse,Jacob Levi,Reaz Mahmud,Sermand Ahmed Mangat,Kaitlyn McCann,Anant Mohan,Mortezza Shakshi Niaee,Nurullah Okumus,Victoria Pilkington,Chinmay Saha Podder,Ambar Qavi,Houssam Raad,Mohammaed Sadegh Rezai,Surapaneni Sasank,Veerapaneni Spoorthi,Tejas Suri,Junzheng Wang,Hannah Wentzel
DOI: https://doi.org/10.21203/rs.3.rs-148845/v1
2021-01-01
Abstract:Abstract Ivermectin is an antiparasitic drug being investigated for repurposing to SARS-CoV-2. In-vitro, ivermectin showed limited antiviral activity and a COVID-19 animal model demonstrated pathological benefits but no effect on viral RNA. This meta-analysis investigated ivermectin in 18 randomized clinical trials (2282 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv and trial registries. Ivermectin was associated with reduced inflammatory markers (C-Reactive Protein, d-dimer and ferritin) and faster viral clearance by PCR. Viral clearance was treatment dose- and duration-dependent. In six randomized trials of moderate or severe infection, there was a 75% reduction in mortality (Relative Risk=0.25 [95%CI 0.12-0.52]; p=0.0002); 14/650 (2.1%) deaths on ivermectin; 57/597 (9.5%) deaths in controls) with favorable clinical recovery and reduced hospitalization. Many studies included were not peer reviewed and meta-analyses are prone to confounding issues. Ivermectin should be validated in larger, appropriately controlled randomized trials before the results are sufficient for review by regulatory authorities.
What problem does this paper attempt to address?